Barclays Maintains Overweight on Barinthus Biotherapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Barinthus Biotherapeutics (NASDAQ:BRNS) but lowers the price target from $7 to $3.
June 13, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Carter Gould maintains an Overweight rating on Barinthus Biotherapeutics (NASDAQ:BRNS) but lowers the price target from $7 to $3.
The lowered price target from $7 to $3 suggests a significant reduction in expected future performance, which is likely to negatively impact the stock price in the short term despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100